drugset
drugset / Trial / NCT03874247

Clinical Trial to Evaluate the Efficacy and Safety of 'Pelubiprofen Controlled Released Tab.' in Acute Traumatic Injury

NCT03874247 ↗

Phase 3 Unknown 94 enrolled Daewon Pharmaceutical Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

A randomized, double-blind, placebo-controlled, parallel, multi-center phase III clinical trial

Timeline

Start
2019-02-25
Primary completion
2019-12-31
Completion
2019-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Pelubiprofen Small molecule 45 mg —

Indications

No indication recorded.